Insmed (INSM) closed at $93.39 on October 23, 2026, down 1.8% from the previous close, on volume of 2,706,481 shares (30-day average 2,564,404).
Data as of October 23, 2026.
23-Oct-2026
Insmed Appoints Two New Directors to Its Board
PRNewswire (Tue, 20-Oct 7:00 AM ET)
PRNewswire (Mon, 19-Oct 7:00 AM ET)
PRNewswire (Thu, 15-Oct 7:00 AM ET)
Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026
PRNewswire (Wed, 14-Oct 7:01 AM ET)
Insmed Sets CFO Exit Date as It Reaffirms 2026 Revenue Guidance for BRINSUPRI and ARIKAYCE
Market Chameleon (Mon, 5-Oct 7:51 AM ET)
Insmed (INSM) CFO to Step Down After Nearly Seven Years as Company Reaffirms 2026 Revenue Guidance
Market Chameleon (Mon, 5-Oct 3:30 AM ET)
Insmed Announces CFO Transition
PRNewswire (Mon, 5-Oct 7:00 AM ET)
PRNewswire (Mon, 21-Sep 7:00 AM ET)
Insmed Expands Community Impact During Fifth Annual Global Day of Good
PRNewswire (Wed, 16-Sep 7:00 AM ET)
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PRNewswire (Fri, 4-Sep 7:01 AM ET)
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Insmed trades on the NASDAQ stock market under the symbol INSM.
As of October 23, 2026, INSM stock price declined to $93.39 with 2,706,481 million shares trading.
INSM has a beta of 0.71, meaning it tends to be less sensitive to market movements. INSM has a correlation of 0.02 to the broad based SPY ETF.
INSM has a market cap of $20.39 billion. This is considered a Large Cap stock.
Last quarter Insmed reported $425 million in Revenue and -$.06 earnings per share. This beat revenue expectation by $36 million and exceeded earnings estimates by $.68.
In the last 3 years, INSM traded as high as $212.75 and as low as $21.92.
The top ETF exchange traded funds that INSM belongs to (by Net Assets): VTI, VXF, VB, VO, VUG.
INSM has underperformed the market in the last year with a price return of -41.7% while the SPY ETF gained +14.3%. INSM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -13.1% and -7.2%, respectively, while the SPY returned +3.2% and -2.4%, respectively.
INSM support price is $92.44 and resistance is $97.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INSM shares will trade within this expected range on the day.
